Community-acquired pneumonia (CAP) is one of the most
frequent infections requiring hospitalization in developed countries
[6]. In COPD patients, CAP is one of the most common infections
[7]. Patients with COPD have structural disruptions in the lung
parenchyma [8] and frequently receive antibiotic and oral or
inhaled steroid treatment. Moreover, COPD is characterized by a
chronic inflammation of the airways [9] and it has been suggested
that patients may present changes in their local and systemic
immune response [10]. For all these reasons, the presentation of
CAP in patients with COPD may differ from that of patients